Internal Neuromodulation Devices Market Report 2026

Internal Neuromodulation Devices Market Overview

• Internal Neuromodulation Devices market size has reached to $2.75 billion in 2025 • Expected to grow to $4.24 billion in 2030 at a compound annual growth rate (CAGR) of 9.2% • Growth Driver: Rising Incidence Of Neurologic Diseases Fuels Growth In The Market Due To Increasing Alzheimer Cases • Market Trend: Digital-Health Innovations Enhance Remote Monitoring And Therapy Optimization In Neuromodulation • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Internal Neuromodulation Devices Market?

Internal neuromodulation devices refer to a type of medical devices that are implanted inside the body to provide electrical stimulation to specific areas of the nervous system. These devices are used to treat various neurological and psychiatric conditions and can significantly relieve patients. The main types of internal neuromodulation devices are spinal cord stimulators, deep brain stimulators, sacral nerve stimulators, vagus nerve stimulators, and gastric neurostimulators. The various types of technologies including internal neuromodulation and external neuromodulation, that includes biomaterials such as metallic biomaterials, polymeric biomaterials, and ceramic biomaterials. These are used for several applications, such as failed back surgery syndrome, Parkinson's disease, urinary incontinence, epilepsy, and gastroparesis, and are used by various end-users, including hospitals, clinics, home healthcare, and community healthcare.

What Is The Internal Neuromodulation Devices Market Growth Forecast?

The internal neuromodulation devices market size is expected to see strong growth in the next few years. It will grow to $4.24 billion in 2030 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to increasing demand for personalized neuromodulation therapies, rising investments in neurotechnology research, expansion of minimally invasive implantation techniques, growing adoption of smart implantable devices, increasing focus on chronic disease management. Major trends in the forecast period include increasing adoption of implantable neuromodulation devices, rising use of rechargeable stimulators, growing integration of adaptive stimulation technologies, expansion of multi-indication neuromodulation applications, enhanced focus on long-term device performance.

What Is The Driver Of The Internal Neuromodulation Devices Market?

The increasing incidence of neurologic diseases is expected to boost the growth of the internal neuromodulation devices market going forward. Neurologic diseases are a broad category of disorders that affect the nervous system, including the brain, spinal cord, and nerves throughout the body. Internal neuromodulation devices are medical devices used to treat neurological and psychiatric disorders by delivering electrical stimulation to specific areas of the nervous system, which can relieve symptoms such as chronic pain, movement disorders, and mood disorders. They can improve patient quality of life by reducing symptoms and allowing them to perform daily activities more easily. For instance, in April 2023, National Library Medicine, a US-based biomedical library, reported that 6.7 million Americans are living with Alzheimer's in 2023, by 2060, this number is projected to rise to 13.8 million. Therefore, the increasing incidence of neurologic diseases is driving the growth of the internal neuromodulation devices industry.

Key Players In The Global Internal Neuromodulation Devices Market

Major companies operating in the internal neuromodulation devices market are Medtronic plc, Boston Scientific Corporation, Abbott Laboratories, LivaNova plc, Nevro Corp., Axonics Modulation Technologies Inc., Saluda Medical Pty Limited, NeuroPace Inc., Aleva Neurotherapeutics SA, EnteroMedics Inc., EndoStim Inc., MicroTransponder Inc., BioControl Medical Ltd., Synapse Biomedical Inc., Neuros Medical Inc., Stimwave Technologies Incorporated, Nuvectra Corporation, Uroplasty Inc., Second Sight Medical Products Inc., NeuroMetrix Inc.

Global Internal Neuromodulation Devices Market Trends and Insights

Major companies operating in the internal neuromodulation devices market are focusing on developing advanced digital-health solutions, such as remote-care platforms, to improve continuous therapy management, reduce in-person clinical visits, and enhance patient safety. Remote-care platforms in neuromodulation refer to digital systems that allow clinicians to monitor device performance, assess patient status, and adjust therapy settings in real time through connected applications. For instance, in April 2023, Biotronik SE & Co. KG, a Germany-based medical technology company, received U.S. FDA approval for its Prospera spinal cord stimulation (SCS) system, which incorporates Embrace One, a next-generation remote-care model designed to deliver automatic, objective, daily remote monitoring and continuous therapy oversight. Designed to support proactive and responsive care, the platform enables clinicians to detect issues earlier, adjust therapy settings remotely, and minimize the need for frequent in-person evaluations. According to Biotronik, Embrace One makes proactive care possible by offering automatic, objective, daily remote monitoring and ongoing management and support, helping strengthen clinical decision-making and long-term patient outcomes.

What Are Latest Mergers And Acquisitions In The Internal Neuromodulation Devices Market?

In April 2025, Globus Medical Inc., a US-based publicly traded musculoskeletal solutions company acquired Nevro Corp. for an undisclosed amount. With this acquisition, Globus Medical aims to expand into new markets for future growth, accelerate the market penetration of Nevro’s differentiated high-frequency spinal cord stimulation technology, and bring much-needed and clinically superior relief to patients suffering from chronic pain, while creating long-term value and enhanced profitability through operational capabilities and global infrastructure Nevro Corp. is a US-based provider of internal neuromodulation devices.

What Defines the Internal Neuromodulation Devices Market?

The internal neuromodulation devices market consists of sales of electrodes, leads, receivers, and others. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Internal Neuromodulation Devices Market Report 2026?

The internal neuromodulation devices market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the internal neuromodulation devices industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.